KKMOH-AG24-BK2

**Borang Penilaian bagi**

**Membangunkan *Clinical Practice Guidelines* (CPG) Baru**

Tajuk Cadangan CPG Baru : ………………………………………………………………………

 ………………………………………………………………………

Nama Penilai : ………………………………………………………………………

Jawatan : ………………………………………………………………………

**Petunjuk Markah:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1 | 2 | 3 | 4 | 5 |

Low / strongly disagree high / strongly agree

|  |  |  |
| --- | --- | --- |
| **Domain** | **Keterangan** | **Markah** |
| *1. Burden of*  *Disease/Condition* | * *What is the incidence /prevalence of clinical topics (Disease/ condition/ circumstances)?*
* *The population (patients, public, etc) to whom the guideline is meant to apply is specifically described?*
* *What is the associated mortality and morbidity?*
* *What are the rates of relapse, complication, re-admission?*
* *Is there reduced quality of life?*
* *Is there patient dissatisfaction?*
 |  |
| *2. Inappropriate / wide variation in clinical practice* | * *Are there gaps between current clinical practice and evidence-based practice?*
* *Are significant variations in practice evident?*
* *What is the associated risk of the variance from best practice?*
* *Would reducing variations incur beneficial effects for patients?*
* *Would reducing variations reduce avoidable morbidity and /or mortality?*
* *To what extent is there a high risk impact for the health system?*
* *Are there high frequency risks factors (avoidable and inherent)?*
 |  |
| *3. Evidence analysis* | * *Are clinical guidelines recommendations based on an analysis of the evidence?*
* *There should be preferably a systematic review of high quality randomized controlled clinical trials or well-designed controlled studies that measure relevant outcomes demonstrating strong, clinically important beneficial public health effects?*
* *Is there detail search method and evidence rating?*
* *Are recommendations graded based on quality of evidence with explicit link between the recommendations and supporting evidence?*
 |  |
| *4. Feasibility of*  *implementation* | * *Are there any significant barriers to implementation of the clinical guidelines?*
* *How acceptable will the clinical guidelines be to relevant stakeholders (consumers and clinicians)?*
* *Is there a degree of urgency for implementation of the guideline?*
* *How accessible will the guideline be?*
 |  |
| *5. Resource Impact* | * *Would implementing this guideline have a substantial budget impact on the healthcare system?*
* *Have the resources implications of implementing the guideline been considered?*
* *Have the resources required for any initial set up or roll out phase been considered?*
* *Have the cost of these resources to the publically funded system been estimated?*
* *Are any potential cost savings to be realized if the guideline is implemented?*
* *Are any potential cost savings due to changes in the use of resources?*
	+ *Have the benefits from improved outcomes been quantified and the associated costs or savings been estimated?*
* *Is there national or international cost-effectiveness evidence to support the implementation of guidelines?*
 |  |
| **Markah Keseluruhan** |  |

Tandatangan,

………………………………………

Tarikh: